Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 64Lymphoma, Large B-Cell, Diffuse 47Lymphoma 33Burkitt Lymphoma 27Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, Non-Hodgkin 14Neoplasms 13Lymphoma, B-Cell 11Lymphoma, T-Cell, Peripheral 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Hodgkin Disease 9Lymphoma, B-Cell, Marginal Zone 8Leukemia 8Recurrence 6Prostatic Neoplasms, Castration-Resistant 6Multiple Myeloma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Neoplasm Metastasis 5Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoproliferative Disorders 4Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Immunoblastic Lymphadenopathy 4Ovarian Neoplasms 3Myasthenia Gravis 3Metastatic Castration-resistant Prostate Cancer 3Melanoma 3

Interventions

enzalutamide 4Docetaxel 3abiraterone 2Prednisone 2Abiraterone Acetate 2relugolix 1pembrolizumab 1olaparib 1lenvatinib 1inavolisib 1belzutifan 1apalutamide 1PF06821497 1Methylprednisolone 1Lutetium-177 1Lutetium 1Gonadotropin-Releasing Hormone 1Etoposide 1Dexamethasone 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Castration-Resistant Prostate Cancer × Prednisone × 1 year × Clear all
NCT02861573 2026-02-17

KEYNOTE-365

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
1,200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
48 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡